<DOC>
	<DOCNO>NCT01065779</DOCNO>
	<brief_summary>This survey conduct prepare application material re-examination Pharmaceutical Affairs Laws Enforcement Regulation , aim reconfirm clinical usefulness FOSAMAX PLUS / FOSAMAX PLUS D collect safety information accord Re-examination Regulation New Drugs . Note : FOSAMAX PLUS D know FOSAMAX PLUS several market . FOSAMAX PLUS ( 70 mg/2800 IU ) FOSAMAX PLUS D ( 70 mg/5600 IU ) .</brief_summary>
	<brief_title>FOSAMAX PLUS FOSAMAX PLUS D Re-examination Study ( 0217A-267 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Participants treat FOSAMAX PLUS / FOSAMAX PLUS D within label first time Participants contraindication FOSAMAX PLUS / FOSAMAX PLUS D accord current local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>